サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1352770

結核検査の世界市場

Tuberculosis Testing
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 423 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
結核検査の世界市場
出版日: 2023年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 423 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

結核検査の世界市場は2030年までに31億米ドルに達する

2022年に20億米ドルと推定される結核検査の世界市場は、2022年から2030年にかけてCAGR 5.7%で成長し、2030年には31億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである培養ベース検査は、CAGR 5.9％を記録し、分析期間終了までに7億5,650万米ドルに達すると予測されます。胸部X線検査セグメントは、今後8年間のCAGRが4.3％と予測されています。

米国市場は1億2,580万米ドル、中国はCAGR6.1％で成長予測

米国の結核検査市場は、2022年に1億2,580万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年までの分析期間においてCAGR 6.1%で推移し、2030年には予測市場規模3億9,700万米ドルに達すると予測されます。その他の注目すべき地理的市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ3.5%と3.9%の成長が予測されています。欧州では、ドイツがCAGR約4.6%で成長すると予測されています。

調査対象企業の例

  • Abbott Laboratories, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • Cepheid
  • Daan Gene Co., Ltd.
  • Akonni Biosystems, Inc.
  • Anatolia Tani ve Biyoteknoloji Urunleri Ar-Ge San. ve Tic. AS
  • Creative Diagnostics
  • Accuquika"¢Test Kits
  • AID GmbH
  • AB ANALITICA s.r.l.
  • Bioneovan Co., Ltd.
  • CTK Biotech, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP16869

What`s New?

» Special discussions on the global economic climate and market sentiment

» Coverage on global competitiveness and key competitor percentage market shares

» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass™ research platform

» Complimentary updates for one year

» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Tuberculosis Testing Market to Reach $3.1 Billion by 2030

The global market for Tuberculosis Testing estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$3.1 Billion by 2030, growing at a CAGR of 5.7% over the period 2022-2030. Culture-Based Tests, one of the segments analyzed in the report, is projected to record 5.9% CAGR and reach US$756.5 Million by the end of the analysis period. Growth in the Chest X-Ray segment is estimated at 4.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $125.8 Million, While China is Forecast to Grow at 6.1% CAGR

The Tuberculosis Testing market in the U.S. is estimated at US$125.8 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$397 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.5% and 3.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Select Competitors (Total 55 Featured) -

  • Abbott Laboratories, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • Cepheid
  • Daan Gene Co., Ltd.
  • Akonni Biosystems, Inc.
  • Anatolia Tani ve Biyoteknoloji Urunleri Ar-Ge San. ve Tic. AS
  • Creative Diagnostics
  • Accuquika"¢ Test Kits
  • AID GmbH
  • AB ANALITICA s.r.l.
  • Bioneovan Co., Ltd.
  • CTK Biotech, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • Year 2021 in Review and Near-term Outlook
    • World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2021, 2022 and 2023
    • COVID-19 Unravels Progress against Tuberculosis & Pushes Mortality for First Time in Decade
    • Tuberculosis, a Disease that Wont Quit: Global Prevalence of Tuberculosis (In 000s) by Geographic Region for the Year 2022
    • Tuberculosis Prevalence Rate Remains High Among Asian Americans: % TB Prevalence in the United States by Race/Ethnicity as of the Year 2022
    • Tuberculosis Prevalence Rate In (%) in the United States by Origin of Birth as of the Year 2022
    • The US Makes Steady Progress Towards TB Elimination: Number of TB Cases for Years 1985, 1995, 2005, 2015, 2020 and 2022
    • Low Funding Remains Palpable Challenge
    • Funding for Tuberculosis is Vital for Reaching the Elimination Threshold Which is Defined as 1 Case Per 1,000,000 People: U.S. Funding for Tuberculosis (In US$ Million) for Years 2001, 2005, 2009, 2013, 2017, 2021, 2023
    • Surge in Tuberculosis Deaths amid COVID-19: A Wake-Up Call to Drive R&D Funding
    • Efforts to Integrate Testing for TB & COVID-19
    • World Market Trajectories
    • Tuberculosis Testing - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Global Market Overview and Outlook
    • Global Tuberculosis Testing Market Exuding High Degree of Vim & Vigor
    • North America Claims Commanding Revenue Share
    • Culture-based Tests & Hospitals: Primary Contributors to Tuberculosis Testing Market
    • Salient Factors Influencing Dynamism of Global Tuberculosis Testing Market
    • Intense Competition Drive Players to Bet on Innovations
    • Molecular Diagnosis Innovations Soaking Up Limelight in the Tuberculosis Testing Arena
    • W.H.O Aims to Improve Access to Rapid Molecular Tests for Diagnosis of TB & Drug-Resistant TB
    • WHO-Endorsed Molecular Platforms & Tests
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Tuberculosis Efforts to Drive the Market for Tuberculosis Testing
    • Bracing Technological Innovations, Tuberculosis Testing Moves in New Direction
    • Tuberculosis Screening: The Dawn of Artificial Intelligence Technology
    • Nanodiagnostics Set to Witness Growth in TB Testing
    • A Nanobiosensor for Rapid Detection of Mycobacterium Tuberculosis
    • CRISPR-based Biosensing to See Significant Growth in Pediatric Tuberculosis
    • Present Limitations and Future Directions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tuberculosis Testing Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tuberculosis Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Culture-Based Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Culture-Based Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 7: World 16-Year Perspective for Culture-Based Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chest X-Ray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chest X-Ray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chest X-Ray by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Interferon-Gamma Release Assay (IGRA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Interferon-Gamma Release Assay (IGRA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Interferon-Gamma Release Assay (IGRA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Mantoux Test (TST) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Mantoux Test (TST) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Mantoux Test (TST) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Smear Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Smear Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Smear Microscopy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Nucleic Acid Testing (NAT) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Serological Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Serological Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for Serological Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Physicians Office by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Physicians Office by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: World 16-Year Perspective for Physicians Office by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: World 16-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • JAPAN
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • CHINA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: China 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: China 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • EUROPE
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Tuberculosis Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • FRANCE
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: France 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: France 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • GERMANY
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Italy 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: UK 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 100: Spain 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 101: Spain Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Spain Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 103: Spain 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 106: Russia 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 107: Russia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Russia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 109: Russia 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Tuberculosis Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 127: Australia 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 128: Australia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Australia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 130: Australia 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • INDIA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 131: India Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 133: India 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 134: India Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 135: India Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 136: India 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 139: South Korea 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 140: South Korea Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 141: South Korea Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 142: South Korea 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Rest of Asia-Pacific Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 148: Rest of Asia-Pacific 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Tuberculosis Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 154: Latin America 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 155: Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Latin America Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 157: Latin America 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 160: Argentina 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 161: Argentina Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Argentina Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 163: Argentina 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 166: Brazil 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 167: Brazil Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Brazil Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 169: Brazil 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 172: Mexico 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 173: Mexico Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Mexico Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 175: Mexico 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 178: Rest of Latin America 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Rest of Latin America Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 181: Rest of Latin America 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Tuberculosis Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 187: Middle East 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 188: Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Middle East Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 190: Middle East 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 193: Iran 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 194: Iran Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Iran Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 196: Iran 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 199: Israel 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 200: Israel Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Israel Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 202: Israel 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 205: Saudi Arabia 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Saudi Arabia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 208: Saudi Arabia 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 211: UAE 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 212: UAE Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 213: UAE Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 214: UAE 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 217: Rest of Middle East 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 219: Rest of Middle East Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 220: Rest of Middle East 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030
  • AFRICA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 223: Africa 16-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2014, 2023 & 2030
    • TABLE 224: Africa Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 225: Africa Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 226: Africa 16-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2014, 2023 & 2030

IV. COMPETITION